Therefore, the role of nimotuzumab in the prevention of angiogenesis in addition to EGFR targeting would be an added advantage in controlling the invasion of head and neck squamous cell carcinoma. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.